References
Epstein CJ (1995) Down syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, vol I, 7th edn. McGraw Hill, Inc, New York, pp 749–794
Pritchard MA, Kola I (1999) The gene dosage effect hypothesis versus the amplified developmental instability hypothesis in Down syndrome. J Neural Transm 57:293–304
Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4:721–729
Beinke S, Ley SC (2004) Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 382:393–409
Sun XF, Zhang H (2007) NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 22:1387–1398
Acknowledgments
This work was supported by the Italian Ministry of Health and ‘5 per mille’ funding.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salemi, M., Barone, C., Romano, C. et al. NF-kB1 gene expression in Down syndrome patients. Neurol Sci 36, 1065–1066 (2015). https://doi.org/10.1007/s10072-014-1981-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-014-1981-4